Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB

Diabetes. 2009 Dec;58(12):2851-62. doi: 10.2337/db09-0685. Epub 2009 Aug 31.

Abstract

Objective: Chronic exposure of pancreatic beta-cells to saturated free fatty acids (FFAs) causes endoplasmic reticulum (ER) stress and apoptosis and may contribute to beta-cell loss in type 2 diabetes. Here, we evaluated the molecular mechanisms involved in the protection of beta-cells from lipotoxic ER stress by glucagon-like peptide (GLP)-1 agonists utilized in the treatment of type 2 diabetes.

Research design and methods: INS-1E or fluorescence-activated cell sorter-purified primary rat beta-cells were exposed to oleate or palmitate with or without the GLP-1 agonist exendin-4 or forskolin. Cyclopiazonic acid was used as a synthetic ER stressor, while the activating transcription factor 4-C/EBP homologous protein branch was selectively activated with salubrinal. The ER stress signaling pathways modulated by GLP-1 agonists were studied by real-time PCR and Western blot. Knockdown by RNA interference was used to identify mediators of the antiapoptotic GLP-1 effects in the ER stress response and downstream mitochondrial cell death mechanisms.

Results: Exendin-4 and forskolin protected beta-cells against FFAs via the induction of the ER chaperone BiP and the antiapoptotic protein JunB that mediate beta-cell survival under lipotoxic conditions. On the other hand, exendin-4 and forskolin protected against synthetic ER stressors by inactivating caspase 12 and upregulating Bcl-2 and X-chromosome-linked inhibitor of apoptosis protein that inhibit mitochondrial apoptosis.

Conclusions: These observations suggest that GLP-1 agonists increase in a context-dependent way the beta-cell defense mechanisms against different pathways involved in ER stress-induced apoptosis. The identification of the pathways modulated by GLP-1 agonists allows for targeted approaches to alleviate beta-cell ER stress in diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Differentiation / metabolism
  • Apoptosis
  • Blotting, Western
  • Cell Survival
  • Colforsin / pharmacology
  • DNA-Binding Proteins / metabolism
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / prevention & control
  • Endoplasmic Reticulum / metabolism*
  • Exenatide
  • Glucagon-Like Peptide 1 / agonists*
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucagon-Like Peptide-1 Receptor
  • Heat-Shock Proteins / genetics
  • Heat-Shock Proteins / metabolism*
  • Hypoglycemic Agents / pharmacology
  • Insulin-Secreting Cells / metabolism*
  • Lipid Metabolism* / drug effects
  • Male
  • Peptides / pharmacology
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-jun / genetics
  • Proto-Oncogene Proteins c-jun / metabolism*
  • RNA Interference
  • Rats
  • Rats, Wistar
  • Receptors, Glucagon / metabolism
  • Regulatory Factor X Transcription Factors
  • Transcription Factors / metabolism
  • Up-Regulation
  • Venoms / pharmacology

Substances

  • Antigens, Differentiation
  • DNA-Binding Proteins
  • GRP78 protein, rat
  • Glp1r protein, rat
  • Glucagon-Like Peptide-1 Receptor
  • Heat-Shock Proteins
  • Hypoglycemic Agents
  • Peptides
  • Ppp1r15a protein, rat
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-jun
  • Receptors, Glucagon
  • Regulatory Factor X Transcription Factors
  • Transcription Factors
  • Venoms
  • Colforsin
  • Glucagon-Like Peptide 1
  • Exenatide